GLP-1 Side Effects & Safety
An educational overview of common and serious GLP-1 side effects, safety warnings, and when to contact a licensed provider. Individual risks vary. This is not medical advice.
Common Effects
Common GLP-1 Side Effects
Most patients experience some mild to moderate effects, especially during the first few weeks. These usually improve over time.
Nausea
The most commonly reported side effect across GLP-1 clinical trials and FDA labeling. Often mild and dose-dependent. Smaller, slower meals and adequate hydration may help. If severe or persistent, contact your licensed provider.
Source: FDA Ozempic / Wegovy labels; MedlinePlus
Vomiting
May occur alongside nausea, particularly after dose increases. Persistent vomiting lasting more than 24 hours requires prompt provider contact to assess dehydration risk and possible dose adjustment.
Source: FDA Ozempic / Wegovy labels
Diarrhea
Loose or watery stools are common during the first 2-3 weeks. Usually self-limited. Maintain hydration. If accompanied by severe abdominal pain, fever, or blood in stool, seek urgent medical care.
Source: FDA Mounjaro / Zepbound labels
Constipation
GLP-1 medications slow gastric emptying, which may lead to constipation. Increasing dietary fiber, fluid intake, and gentle physical activity may help. Discuss persistent constipation with your provider.
Source: FDA Ozempic / Wegovy labels; MedlinePlus
Abdominal discomfort & bloating
Cramping, gas, and a sensation of fullness are common as digestion slows. These typically improve with time. If pain is severe or persistent, contact your provider promptly.
Source: FDA Ozempic / Wegovy labels
Decreased appetite
Reduced hunger and early satiety are the intended therapeutic effects of GLP-1 therapy. However, some patients may eat too little, risking inadequate nutrition. Discuss any concerns about caloric intake with your provider or a registered dietitian.
Source: FDA Ozempic / Wegovy labels
Side effect profiles vary by individual, dose, medication type, and titration speed. Your licensed provider will discuss what you may expect based on your specific health profile.
Urgent
Serious Warning Signs
Know when to contact your licensed provider urgently or seek emergency care.
Contact Your Provider Promptly
Severe or persistent abdominal pain
Intense pain, especially in the upper abdomen or radiating to the back, may signal gallbladder or pancreatic issues.
Signs of dehydration
Dark urine, dizziness, dry mouth, rapid heartbeat, or reduced urination — especially if vomiting or diarrhea are present.
Persistent vomiting
Vomiting lasting more than 24 hours or preventing fluid intake. Dehydration can occur quickly.
Yellowing skin or eyes
Jaundice may indicate gallbladder obstruction or liver dysfunction. Requires urgent evaluation.
Seek Emergency Care (Call 911)
Difficulty breathing or swallowing
May indicate a severe allergic reaction (anaphylaxis) requiring immediate emergency treatment.
Severe rash, swelling, or hives
Sudden skin changes with facial or throat swelling after an injection are emergency symptoms.
Chest pain or severe shortness of breath
While not a known direct effect of GLP-1s, any new chest symptoms require immediate evaluation.
Fainting or severe weakness
May indicate severe dehydration, low blood sugar, or another acute condition requiring emergency care.
When in doubt, contact your provider. For medical emergencies, do not wait — call 911 or go to the nearest emergency room. This guide is educational only and does not replace clinical judgment.
Contraindications
Who Should Not Use GLP-1 Therapy
GLP-1 receptor agonists are not appropriate for everyone. Your licensed provider will review your complete medical and family history before prescribing. Certain conditions and histories make GLP-1 therapy inadvisable or contraindicated.
Personal or family history of MTC
Medullary thyroid carcinoma (MTC) is a rare thyroid cancer. GLP-1 medications carry a boxed warning based on animal studies. Patients with a personal or family history of MTC should not use GLP-1 therapy.
Source: FDA Ozempic / Wegovy / Mounjaro labels
Multiple Endocrine Neoplasia type 2 (MEN 2)
MEN 2 is a genetic syndrome that increases the risk of thyroid and other endocrine tumors. GLP-1 therapy is contraindicated in patients with MEN 2.
Source: FDA Ozempic / Wegovy / Mounjaro labels
Active pancreatitis
Patients with a history of pancreatitis or active pancreatic disease require careful evaluation. GLP-1 therapy may increase pancreatic risk in susceptible individuals.
Source: FDA Ozempic / Wegovy labels
Severe gastrointestinal disease
Conditions such as severe gastroparesis or inflammatory bowel disease may be worsened by slowed gastric emptying. Your provider will evaluate your GI history.
Source: Clinical consensus
This is not an exhaustive list. Your licensed provider will conduct a full review of your health history, current medications, and risk factors before determining whether GLP-1 therapy is appropriate for you. Not all patients qualify.
Comparison
Semaglutide vs. Tirzepatide: Safety Overview
Both medications have overlapping safety profiles with important differences. Neither is universally safer. Individual response determines tolerability.
| Aspect | Semaglutide | Tirzepatide |
|---|---|---|
| Most common GI effects | Nausea, vomiting, diarrhea, constipation | Nausea, vomiting, diarrhea, constipation |
| Typical GI severity | Moderate; often improves over 2-4 weeks | Moderate to significant; may be more pronounced at higher doses in some patients |
| Hypoglycemia risk (alone) | Low when not combined with insulin or sulfonylureas | Low when not combined with insulin or sulfonylureas |
| Thyroid C-cell warning | Boxed warning; contraindicated with MTC/MEN2 history | Boxed warning; contraindicated with MTC/MEN2 history |
| Pancreatitis risk | Caution in patients with prior pancreatitis | Caution in patients with prior pancreatitis |
| Gallbladder events | Increased risk of cholelithiasis reported in trials | Increased risk of cholelithiasis reported in trials |
| Injection site reactions | Mild redness or itching at injection site | Mild redness or itching at injection site |
| Individual tolerability | Varies significantly by patient | Varies significantly by patient |
Neither semaglutide nor tirzepatide is universally safer or better tolerated for all patients. Your licensed provider will select the most appropriate option based on your individual health profile, prior experiences, and clinical goals. Sources: FDA labels for Ozempic, Wegovy, Mounjaro, and Zepbound.
Compounded Products
Compounded Medication Considerations
Understanding the difference between compounded and FDA-approved products helps you make an informed decision with your provider.
FDA-Approved Brand Products
- Manufactured under strict FDA Good Manufacturing Practice (GMP) regulations
- Extensive clinical trial data on efficacy and safety profiles
- Standardized dosing, packaging, and labeling
- Typically higher cost; insurance coverage varies
- Subject to FDA post-market surveillance and adverse event reporting
Compounded Products
- Prepared by state-licensed compounding pharmacies
- Prepared by licensed compounding pharmacies
- Used when commercially manufactured products are in shortage or unavailable
- Quality ensured through USP <795>/<797> compliance and pharmacy testing
- Your provider discusses risks and benefits before prescribing compounded therapy
Important: Compounded semaglutide and tirzepatide have not undergone the same clinical testing as brand-name medications. All prescribing decisions are made by independent licensed providers who will discuss whether compounded therapy is appropriate for your case. Open Water Rx does not manufacture, compound, or dispense medications. Source: FDA compounding pharmacy guidance; USP <795>/<797>.
Provider Contact
When to Contact Your Licensed Provider
Your provider is available through secure messaging. Know when to reach out versus when to seek emergency care.
Message Your Provider
Use secure messaging for: side effect questions, concerns about tolerability, questions about diet or exercise, missed dose guidance, or any new symptom that worries you. Response time is typically within 24 hours during business days.
Seek Urgent Care
Go to urgent care for: severe abdominal pain with fever, signs of dehydration that do not improve with fluids, persistent vomiting beyond 24 hours, or gallbladder symptoms (upper right pain, nausea, jaundice).
Call 911
Call emergency services for: difficulty breathing or swallowing, severe allergic reactions with swelling, chest pain, fainting, or any symptom you believe is life-threatening. Do not wait for a provider response in emergencies.
Safety Guidelines
What Patients Should Not Do Without Provider Guidance
GLP-1 therapy requires ongoing provider oversight. These are the most important safety rules to follow.
Do not change your dose
Never increase, decrease, skip, or double your dose without explicit provider instruction. Dose changes must be supervised to ensure safety and efficacy.
Do not share your medication
Your prescription is individualized for your health profile. Sharing GLP-1 medication with others is illegal and potentially dangerous.
Do not combine with other weight loss drugs
Do not use GLP-1 therapy alongside other prescription weight loss medications, unregulated supplements, or stimulants without provider approval.
Do not pursue extreme diets
Very-low-calorie diets, prolonged fasting, or extreme exercise regimens can worsen side effects and compromise muscle mass. Discuss any major diet changes with your provider.
Do not ignore severe side effects
Persistent vomiting, severe abdominal pain, signs of dehydration, or allergic reactions require prompt provider contact or emergency care.
Do not stop abruptly without guidance
If you want to stop or pause treatment, contact your provider first. Abrupt discontinuation can lead to rebound appetite and rapid weight regain.
Eligibility
Eligibility & Provider Review
Final eligibility is determined by an independent licensed medical provider after reviewing your complete health profile. Not all patients qualify.
May Be Considered For
- Adults 18+ with BMI 27+ and a weight-related health condition (or BMI 30+)
- Those who have made prior diet and lifestyle modification attempts
- Patients with no contraindications (no MTC/MEN2 history, no active pancreatitis)
- Patients willing to commit to ongoing provider monitoring and follow-up
May Not Be Appropriate For
- Patients with personal or family history of MTC or MEN 2
- Patients with active pancreatitis or severe gastrointestinal disease
- Pregnant or breastfeeding patients
- Patients under 18 years of age
Delivery & Privacy
Shipping & Privacy
If prescribed, your medication is prepared by a licensed compounding pharmacy and shipped directly to your door. Shipping is included in your monthly plan price.
Discreet Packaging
Plain, unmarked packaging with no external branding or medication labels visible.
Cold-Chain Shipping
Refrigerated medications ship with appropriate cold-chain packaging to maintain efficacy.
HIPAA-Compliant
Your health data is encrypted end-to-end. We never sell your data or share it without consent.
Shipping is available to any valid U.S. address for prescribed medications, though which medications can be prescribed depends on your state's regulations and provider review.
FAQ
Safety Questions Answered
The most commonly reported side effects of GLP-1 receptor agonists include nausea, vomiting, diarrhea, constipation, abdominal discomfort, bloating, and decreased appetite. These effects are usually mild to moderate and often improve as your body adjusts to the medication over several weeks. Individual experiences vary significantly. Some patients experience minimal side effects, while others may need additional support or dose adjustments under provider supervision.
Most gastrointestinal side effects such as nausea, vomiting, and diarrhea are most pronounced during the first 2-4 weeks and tend to improve with continued use. Some patients may experience ongoing mild symptoms at higher doses. The gradual titration approach used by licensed providers is specifically designed to help your body adapt slowly, which may reduce both the intensity and duration of side effects. If side effects persist beyond 4-6 weeks or worsen, contact your licensed provider to discuss your options.
Contact your licensed provider promptly if you experience severe or persistent abdominal pain, signs of dehydration (dark urine, dizziness, rapid heartbeat, dry mouth), persistent vomiting lasting more than 24 hours, yellowing of skin or eyes, upper right abdominal pain with fever, difficulty breathing, severe rash, or swelling after an injection. For life-threatening symptoms or medical emergencies, call 911 or go to the nearest emergency room immediately.
GLP-1 receptor agonists carry a boxed warning about thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). This warning is based on animal studies. In humans, the risk is not definitively established. However, GLP-1 therapy is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Your licensed provider will review your medical and family history before prescribing and will discuss this risk with you during your consultation.
Both semaglutide and tirzepatide affect GLP-1 receptors and share many of the same gastrointestinal side effects, including nausea, vomiting, diarrhea, and constipation. Because tirzepatide also activates GIP receptors, some patients may experience different side effect patterns or intensity compared to semaglutide. Neither medication is universally better tolerated than the other — individual responses vary. Your licensed provider will select the most appropriate medication and dosing approach based on your health profile, prior experiences, and treatment goals.
Compounded medications are prepared by state-licensed compounding pharmacies to meet individual patient needs when commercially manufactured products are in shortage or unavailable. Compounded products have not undergone the same clinical trials as brand-name medications such as Wegovy, Ozempic, or Mounjaro. Their safety, purity, and potency are ensured by the compounding pharmacy's quality control processes and compliance with USP standards. Your licensed provider will discuss whether compounded therapy is appropriate for your case. Open Water Rx does not manufacture, compound, or dispense medications.
Side effects cannot be fully prevented, but their impact may be reduced through gradual dose titration under provider supervision, adequate hydration, smaller and slower meals, and avoiding alcohol and high-fat foods during the adjustment period. These strategies may help but do not eliminate the possibility of side effects. Individual responses vary. Discuss any concerns with your licensed provider before starting therapy.
Do not stop, skip, or change your medication dose without first consulting your licensed provider. Mild to moderate side effects often improve over time. Your provider may recommend supportive measures, temporary dose adjustments, or other interventions. Abruptly stopping GLP-1 therapy can lead to rapid return of appetite and potential weight regain. Any decision to pause or discontinue treatment should be made with your provider.
GLP-1 receptor agonists can slow gastric emptying, which may affect the absorption of other oral medications. Tell your licensed provider about all prescription medications, over-the-counter drugs, supplements, and herbal products you take. Particular attention is needed for medications with narrow therapeutic windows, such as certain thyroid medications and immunosuppressants. Your provider will review your medication list and adjust timing or dosing of other drugs if needed.
Never change your dose, skip doses, double doses, or stop medication without consulting your provider. Never share your prescription with anyone else. Never combine GLP-1 therapy with other weight loss medications or unregulated supplements without provider approval. Never pursue extreme diets, prolonged fasting, or intense exercise regimens without discussing them with your provider first. Never ignore persistent or severe side effects. Always follow your provider-prescribed plan.
Have Questions About Side Effects?
Connect with a licensed provider who can review your health history, discuss potential side effects, and determine if GLP-1 therapy is appropriate for you. Not all patients qualify. Available nationwide in all 50 states.
Check My EligibilityExplore More
Beginner's Guide
What to expect your first month on GLP-1 therapy.
Semaglutide
GLP-1 receptor agonist overview, dosing, and safety.
Tirzepatide
Dual GIP/GLP-1 receptor agonist overview and safety.
Oral GLP-1
Non-injection daily tablet options when appropriate.
Patient FAQ
Am I Eligible?
Check your eligibility for GLP-1 treatment. Available nationwide in all 50 states.
How It Works
The full 5-step telehealth process from evaluation to delivery.
State Availability
See where GLP-1 programs are available across the U.S.
Check your state →
Important FDA Notice: Compounded semaglutide and tirzepatide are not FDA-approved finished drug products. This page is for educational purposes only and is not a substitute for professional medical advice. All prescribing decisions are made by independent licensed medical providers. A valid patient-provider relationship must be established before any prescription is issued. Open Water Rx does not manufacture, compound, or dispense medications. Available nationwide in all 50 states. Read full consent →